Anamed Title:
ANAMED Title Deneme Mater

Placeholder

Date

2025

Institution Author

Departments

School / College / Institute

Program

KU-Authors

Koç University Affiliated Author

Koc Author

KU Authors

Co-Authors

Co Authors

Editor & Affiliation

Compiler & Affiliation

Translator

Other Contributor

Language

tur

Type

Book

Journal Title

Volume Title

Alternative Title

Alternatif Title Deneme Mater

Abstract

Abstract

Source

Publisher

Publisher

Subject

Subjects

Citation

Has Part

Book Series Title

Book Series Title

DOI

10.00_Sina

URI

https://doi.org/10.00_Sina
 https://hdl.handle.net/20.500.14288/31369

item.page.datauri

Link

Other Links

Rights

All Rights Reserved by Koç University

Rights URI

Grant No

Grant No Deneme

Sponsors

Sponsorship deneme

Copyrights Note

Related Research Data

Collections

ANAMED Titles

Endorsement

Review

Supplemented By

Referenced By

Related Publication

Placeholder
PublicationMetadata only
Clinical variance in an international cohort of families with dominant-negative FOXN1 mutations
(Rockefeller University Press, 2025) Alper, Ezgi Nur; Evan Potts; Philip Mendez; Serena Shaffren; Paola Suhet; Emily Ammon; Marita Bosticardo; Christian Wysocki; Nicolai Van Oers; John Sleasman; Marco Yamazaki-Nakashimada; Safa Baris; Svetlana Sharapova; Luigi Notarangelo; Austen Worth; Alexandra Kreins; Jolan Walter; School of Medicine; SCHOOL OF MEDICINE
Transcription factor Forkhead box protein N1 (FOXN1) regulates thymic epithelial cell development. Bi-allelic and compound heterozygote loss-of-function mutations result in nude-severe combined immune deficiency with athymia, alopecia, and nail dystrophy requiring thymus transplantation. Dominant-negative heterozygous variants have incomplete and highly variable phenotypes. We present an international cohort of families carrying dominant negative mutations with variable clinical presentation, course, and outcomes. Methods Patient medical records and diagnosing physicians were consulted. Results We have access to 11 FOXN1 dominant-negative heterozygotes from 4 families with highly variable intrafamilial clinical courses and management. All variants locate near the C terminus, like variants in Rota et al. [1]. Immunological phenotype included 5/11 with Omenn syndrome (OS) early in life, otherwise presenting as asymptomatic (2/11) or with T cell lymphopenia (4/11), characterized by persistently low naïve T cells, and specific antibody deficiency (1/11) even in middle age. Alopecia and/or nail dystrophy was only noted in 1/11 patients. OS treatments ranged from conservative management (1/5), short-term steroids (1/5), long-term prednisolone alone (1/5), cyclosporine and prednisolone (1/5), and 1/5 OS patients received a bone marrow transplant prior to genetic diagnosis and later expired. (3/11) patients were placed on immunoglobulin replacement therapy. Only 3/11 patients experienced adverse outcomes, with 1/11 deaths. Other adverse outcomes include severe herpesviridae infections: Varicella pneumonia and CMV retinitis, respectively. 2/11 patients experienced EBV viremia and 2/11 with CMV viremia. 1/2 families tested were positive for anti-IFNα autoantibodies. Only one patient is being considered for thymic transplant. Conclusions This cohort demonstrates intrafamilial variability ranging from asymptomatic symptoms to OS, which has seldom been described in athymia patients. Heterogeneity indicates a need for distinct longitudinal treatment protocols for dominant negative FOXN1 patients, including lifelong protective immunoglobulin replacement therapy, and the possibility of thymic transplant for best outcomes, which has not been performed in FOXN1 heterozygotes before.

Related Anamed Other

Placeholder
Anamed OtherMetadata only
ANAMED Other Publication Title Deneme Mater
(Publisher, 2025) Co Authors; Compiler; University; Editör; University; Koc Author; Other Contributor; Translator
Abstract
Placeholder
Anamed OtherMetadata only